Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
29 participants
INTERVENTIONAL
2024-06-05
2026-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Human Induced Neural Stem Cell-derived Exosomes for Treating Acute Ischemic Stroke
NCT07143786
Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke
NCT03384433
BXOS110 Injection in the Treatment of Acute Ischaemic Stroke
NCT06322394
Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke
NCT04950790
The Safety and Efficacy of NouvSoma001 in Ischemic Stroke
NCT06612710
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A traditional 3+3 dose escalation design will be implemented in part 1. Cohort 1: receive 2×10\^9 particles/kg; cohort 2: 4×10\^9 particles/kg and cohort 3: 8×10\^9 particles/kg. If no dose-limiting toxicities (DLTs) are observed for 2 weeks after administration of the first injection, a new cohort will be enrolled at the next planned dose level. If DLTs are observed in 1 participant in the cohort, another 3 participants will be treated in the same dose level. Dose escalation will be stopped until DLTs are observed in \>33% of the participants.
In part 2, 20 subjects will be randomized in a 1:1 ratio \[exosome (n=10) or exosome placebo (n=10)\]. The dose level will be determined by Data Safety Monitoring Board based on part 1.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exosomes group
Patients in this arm will be given exosomes derived from human induced pluripotent stem cell for injection once a day for 7 days.
exosomes derived from human induced pluripotent stem cell for injection
Exosomes derived from human induced pluripotent stem cell for injection (3.0ml, 1×10\^11particles/ml).
Exosomes placebo group
Patients in this arm will be given a placebo of exosomes derived from human induced pluripotent stem cell for injection once a day for 7 days.
a placebo of exosomes derived from human induced pluripotent stem cell for injection
Exosomes placebo, 3.0ml
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
exosomes derived from human induced pluripotent stem cell for injection
Exosomes derived from human induced pluripotent stem cell for injection (3.0ml, 1×10\^11particles/ml).
a placebo of exosomes derived from human induced pluripotent stem cell for injection
Exosomes placebo, 3.0ml
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-70 years, inclusion of both genders
* Modified Rankin Scale score before stroke of 0-1
* NIHSS score 6-20 at inclusion that did not change by ≥4 points from screening to baseline assessment.
* Time of stroke onset is known and treatment can be started between day 1 and 7 of onset.
* Confirmation of hemispheric cortical infarct with magnetic resonance imaging or computed tomography
* Subjects who received intravenous thrombolysis or underwent mechanical reperfusion are eligible if they meet all other eligibility criteria.
* Adequate hepatic and renal function: serum aspartate aminotransferase ≤2.5× upper limit of normal; serum alanine aminotransferase ≤2.5× upper limit of normal; blood urea nitrogen ≤1.25× upper limit of normal; serum creatinine ≤1.25× upper limit of normal
* Adequate cardiac function.
* Subjects or legal representative can sign the informed consent and must be willing and able to comply with all aspects of treatment and follow-up schedule.
Exclusion Criteria
* Presence of a lacunar or a brainstem infarct as the etiology of current symptoms.
* Evidence of brain tumor or history of epilepsy or traumatic brain injury.
* Subjects with present malignant disease.
* Subjects with severe comorbidities including immunodeficiency or coagulation disorders.
* Subjects with Alzheimer's disease, Parkinson's disease or other degenerative neurological disease.
* Ongoing systemic infection, severe local infection or taking immunosuppressants.
* Subjects with positive hepatitis B surface antibody (HBsAg) and positive hepatitis B core antibody (HBcAb), or HBsAg-positive virus carriers, positive hepatitis C antibody, positive syphilis antibody or HIV
* Allergy to the study products.
* Documented allergies
* Participation in any clinical trial in the last 3 months
* Inability or unwillingness to comply with the study schedule
* Pregnancy, childbearing potential (unless it is certain that pregnancy is not possible), oe breast feeding
* Other serious medical or psychiatric illness that is not adequately controlled
* Other circumstances that the investigator considers inappropriate for participation in the trial.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guidon Pharmaceutics Ltd.
INDUSTRY
Xuanwu Hospital, Beijing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Junwei Hao, MD
Director of Neurology Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Junwei Hao, MD; PhD
Role: PRINCIPAL_INVESTIGATOR
Xuanwu Hospital, Beijing
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xuanwu Hospital, Capital Medical University
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XMEC-2023-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.